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Summary 
Human immunodeficiency  virus type 1 (HIV-1), in contrast to animal retroviruses such as murine 
leukemia virus, is not lysed by human complement. Nevertheless,  HIV-1 activates complement 
via the classical pathway independent of antibody, and C3b deposition facilitates infection of 
complement receptor-bearing cells. Using gel exclusion chromatography on Sephacryl S-1000, 
purified virions were found to bind 12sI-1abeled Clq, but not 12SI-labeled dimeric proenzyme 
Cls. Virions activated the C1 complex, reconstituted from Clq, proenzyme Clr, and 12SI-labeled 
proenzyme Cls, to an extent comparable with that obtained with immunoglobulin G-ovalbumin 
immune complexes.  To determine the activating viral component, recombinant viral proteins 
were used: in the solid phase, soluble gp41 (sgp41) (the outer membrane part of gp41, residues 
539-684 of gp160) bound Clq, but not dimeric proenzyme Cls, while gp120 was ineffective. 
In the fluid phase, sgp41 activated the C1 complex in a dose- and time-dependent manner, more 
efficiently than aggregated Ig, but less efficiently than immune complexes.  To localize the C1 
activating site(s) in gp41, synthetic peptides (15-residue oligomers spanning amino acids 531-695 
of gp160) were used. Peptides covering positions 591-605  and 601-620 and, to a lesser extent, 
positions 561-575, had both the ability to bind Clq and to induce C3 deposition. These data 
provide the first experimental evidence of a direct interaction between the C1 complex and HIV-1, 
and indicate that C1 binding and activation are mediated by specific sites in gp41. 
i~ 
troviruses isolated from avian, feline, murine, and simian 
sources have been found to be lysed by normal human 
serum (1-3). Lysis is induced by direct antibody-independent 
triggering of the classical complement pathway (4). It was 
previously believed  that this mechanism protected the in- 
dividual from retroviral disease (2). Human retroviral patho- 
genes (HIV-1 and HTLV-1) have since been identified, and 
several laboratories have shown that these viruses are not lysed 
e~ciently by human serum (5, 6), although animal sera from 
felidae or muridae are capable of lysis (7). 
As in the case with other retroviruses,  cells infected with 
HIV-1 activate the complement system independent of anti- 
body via the alternative pathway. Subsequent deposition of 
C3b/C3d resulted in rosetting between HIV-l-infected cells 
and cells bearing complement receptors (CR)  (8).  In con- 
trast, isohted HIV-1 (strain IIIB) activated the dassical pathway 
independent of antibody (8). The biological relevance of the 
latter mechanism was demonstrated through the observation 
that infection of CR-bearing cells by HIV-1 is enhanced at 
low multiplicity of infection (9,  10), i.e., under conditions 
that probably represent the typical in vivo situation during 
the first contact between HIV-1 and the host. The validity 
of this concept has been proven by other groups (11-13). 
The fact that complement activation by HIV-1 does not 
result in lysis of the virus could be explained either by a viral 
component interfering with the complement cascade or by 
restriction mechanisms similar to those protecting cells of 
an individual against its own complement system (14, 15), 
such as decay-accelerating factor (16) and membrane cofactor 
protein (17); such a factor originating from the host cell may 
be embedded in the membrane of HIV-1  and protect the 
retrovirus against the lytic activity of human complement. 
Among examples of such a protection mechanism in other 
viruses is glycoprotein C of HSV-1, which binds C3b (18); 
vaccinia virus has a protein with structural homology to C4b- 
binding protein (19) and EBV accderates the decay of the 
alternative pathway C3 convertase  (20,  21). 
In an attempt to elucidate the molecular mechanisms in- 
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pathway of complement by HIV-1, we provide the first ex- 
perimental evidence of a direct interaction between the C1 
complex and HIV-1  and show that C1 binding and activa- 
tion are mediated by specific sites in gp4L 
Materials and Methods 
Reagents and Buffers.  IgG-OVA  immune complexes were pre- 
pared at equivalence  as described  previously (22). Heat-aggregated 
Igs were prepared by heating purified rabbit Ig (15 rag/m1) for 15 
rain at 63~  Particulate material was removed by centrifugation 
and the soluble aggregates were used for C1 activation. 
Veronal-buffered saline (VBS)  1  contained 5 mM sodium barbital 
(pH 7.4), 0.15 mM CaC12, 1 mM MgCI2, and either  150 mM 
NaC1 (physiological ionic  strength)  or  75  mM  NaC1 (half- 
physiological  ionic strength). Recombinant protein p138 from EBV 
was obtained from Biotest (Dreieich, Germany). 
C1 Subcomponents.  Clq, proenyzme Clr, and proenzyme Cls 
were isolated from human plasma as described  previously (22, 23). 
The concentrations of  purified Clq, Clr, and Cls were determined 
by using values ore (1%, 1 cm) at 280 nm of 6.8, 12.4, and 14.5, 
and molecular weights of 459,300, 86,300, and 78,900 (24, 25). 
Clq and Cls were labeled with 12sI either by the immobilized 
lactoperoxidase-glucose  oxidase  method using Enzymobeads (Bio- 
Rad Laboratories,  Richmond, CA) or with Iodobeads  (Pierce Chem- 
ical Co., Rockford, IL) as recommended  by the manufacturers.  Un- 
bound 12sI was removed by exhaustive dialysis or by centrifuga- 
tion on a Sephadex G 50 fine column (Pharmacia Fine Chemicals, 
Uppsala, Sweden) as described previously (26). 
Cells and Virions Pre~ration.  H9 ceils  chronically  infected with 
HIV-1 (HTLV-IIIB  strain) were cultivated with four parts of unin- 
fected H9 cells  in RPMI 1640 supplemented  with 10% FCS, 2 mM 
glutamine,  and  antibiotics (all from  Seralab, Sussex, UK)  for 
48-72 h. Supernatants were harvested by centrifugation at 400 g 
for 10 min, followed by centrifugation at 800 g for 30 min, and 
subsequent filtration through a 0.2-#m membrane (Millipore Con- 
tinental Water Systems,  Molsheim,  France). These supematants  were 
centrifuged at 100,000 g for 90 rain to concentrate the virus. Virus 
was resuspended  in 500 #1 of  VBS at half-physiological  ionic strength 
and loaded under containment conditions onto a disposable 10-ml 
Sephacryl S-1000 column (Pharmacia Fine Chemicals) equilibrated 
with the same  buffer. Virions were eluted with this buffer and frac- 
tions were collected. P24 was measured with a capture ELISA 
(Coulter Immunology, Hialeah, FL) using recombinant p24 as a 
standard (27). In parallel, supernatants of  uninfected H9 cells were 
centrifuged, passed through the column, and used as a control. 
Proteins and Peptides  from HIV-I.  Recombinant protein gp120 
(HTLV-IIIB strain) was obtained from the MRC AIDS Directed 
Program (Hefts, UK). Soluble gp41 (sgp41), the proposed outer 
membrane part of gp41 (28), was derived from clone BH 10. The 
restriction sites RsaI and SspI were used to clone this fragment 
into the plasmid  pSB6 and generate the expression  of a 18-kD poly- 
peptide (amino acids 539-684 of gp160) in Escherichia coil It was 
purified to homogeneity by a three-step method (27). Before use 
for activation studies, the final preparation, in 0.1 M Tris-HC1 (pH 
9.0) containing 0.2% SDS, 0.3 M urea, 10% glycerol, and 14 mM 
B-mercaptoethanol, was submitted to several  dialysis  cycles  against 
the appropriate  buffer,  using a microdialyzer  (Pierce Chemical  Co.). 
Synthetic peptides Env 54-Env 69 (29) (15-residue oligomers with 
t Abbreviation used in this paper: VBS, veronal-buffered  saline. 
five-amino  acid  overhp) covering  positions 531-695 of gp160 (HIV-1 
strain SF-2) were either kindly provided by Dr. J. Denner (Frank- 
furt, Germany)  or obtained  from the MRC AIDS Directed  Program. 
Gel Exclusion Chromatograpt~.  Gel exclusion chromatography 
was performed as described (30-32). Briefly,  100-/~1 samples of  virus 
(1.5 #g of p24/ml) were incubated with either 1 #g of mI-labded 
Clq (112,000 cpm/#g) or 1 #g of 12q-labeled dimeric proenzyme 
Cls (98,000 cpm/#g) for 30 min at room temperature in VBS at 
half-physiological  ionic strength and loaded onto 2-ml disposable 
Sephacryl S-1000 columns equilibrated with the same  buffer. Virus 
was eluted from the column, and 250-#1 fractions were collected. 
Virus was neutralized by addition of Triton X-100 to 1%. Each 
fraction was assayed for mI radioactivity and p24. 
Clq (Cls) Binding Assay.  Clq and Cls were radiolabeled  by the 
immobilized  hctoperoxidase-glucose  oxidase  method (33). Recom- 
binant proteins (100 ng) were incubated in ELISA  plates (Immuno- 
plate, Maxisorb; Nunc, Roskilde,  Denmark) in a carbonate-buffered 
saline (pH 9.6) and left overnight at 4~  Synthetic peptides (1 
#g/weU)  were dried  onto  ELISA plates  at  30~  overnight. 
Nonspecific binding was blocked by two incubations for 30 min 
at room temperature with 100 #1 of 1% BSA in VBS at half- 
physiological  ionic strength, followed by one wash with the same 
buffer. Binding was performed by incubation for 30 rain at room 
temperature  with  either  50  #1  of  12SI-labeled Clq  (50,000 
cpm/well) or 50 #1 of 12q-labeled dimeric proenzyme Cls (50,000 
cpm/well). Plates were washed three times with the same buffer 
containing 0.05% Tween 20. Bound Clq or Cls was removed by 
addition of 100 #1 of 1 M NaOH/well and measured by counting 
12sI radioactivity. 
C1 Activation Assay.  Proenzyme C1 was reconstituted to a con- 
centration of 1 #M by incubating 12q-labeled Cls (26,000-30,000 
cpm/#g), Clq and Clr (Clq/Clr/Cls molar ratios of 1:2:2), for 
5 min at 4~  in the presence of 2.5 mM CaCI2, either in VBS 
at half-physiological  ionic strength (activation by HIV-1) or in 145 
mM NaC1, 50 mM triethanolamine-HC1, pH 7.4 (activation by 
recombinant proteins). 20 #1 of viral suspension (p24; 1.5 #g/ml) 
or of protein solution (0.14-2.0 mg/ml) in the appropriate buffer 
was incubated with 1-12 #g of reconstituted C1 in a final volume 
of 40 #1 for various periods at 30~  Activation of radiolabded 
Cls in C1 was measured  by monitoring the conversion  of the proen- 
zyme form to its activated two-chain counterpart by SDS-PAGE 
(34) under reducing conditions. This was performed either by di- 
rect measurement of 12sI radioactivity  on the dried gels or by scan- 
ning of autoradiographs. 
C3-Deposition ELISA.  Synthetic  peptides (1 #g/well) were dried 
onto ELISA plates at 30~  overnight. Nonspecific binding was 
blocked by incubation with 100 #1 of 1% BSA in VBS at physio- 
logical ionic strength for 1 h at room temperature. After one wash 
with the same  buffer, 50 #1 of 5% normal human serum (confirmed 
as negative  for antibodies  against HIV-1 by HIV-1 ELISA  and HIV-1 
Western blot) in VBS was added and incubation was performed 
for 20 rain at 30~  C3 deposition was detected by a rabbit poly- 
clonal anti-C3d antibody (Dakopatts, Glostrup, Denmark) followed 
by peroxidase-conjugated  anti-rabbit Ig antibody  (Dakopatts). Color 
was developed  with 1 mM 2,2'-Azino-di-(3-ethylbenzthiazoline  sul- 
fonate) (ABTS) (Sigma Chemical Co.) and 0.002% (vol/vol) HzO2 
in citrate buffer (pH 4.3) and optical densities were determined 
at 412 nm. 
Results 
Clq, but Not Cls, Binds to HIVI.  Since  classical  pathway acti- 
vation by HIV-1 has been proven (8), we wanted to determine  which 
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m_  Figure  1.  Clq  (Cls)  binding  to 
HIV-1. 12SI-hbeled  Clq (.4) or Cls (B) 
were incubated with HIV-1 and then 
subjected to gel exclusion chromatog- 
raphy on Sephacryl  S-1000. (rq and II) 
12sI; (O  and  O) p24; (closed symbols 
and continuous lines) samples containing 
HIV-1; (open symbols and dotted lines) 
samples containing control preparation. 
C1 subcomponent(s) is (are) involved in the interaction between 
the C1 complex and HIV-1. To this end, gel exclusion chromatog- 
raphy on Sephacryl S-1000 was used because of its ability to sepa- 
rate virions from proteins. Preliminary experiments indicated that 
virions eluted between 1.0 and 1.5 ml, as demonstrated by p24 cap- 
ture F_LISA, whereas free Clq and free dimeric proenzyme Cls eluted 
between  1.75  and 2.5  ml. As shown in Fig.  1 A, when virions 
were preincubated with Clq, part ofClq coduted with the virions. 
In control experiments, the elution position of Clq was not modified 
after incubation with the control preparation (uninfected H9 su- 
pematants prepared in parallel to virions). In contrast, experiments 
performed with dimeric proenzyme Cls gave no evidence for an 
interaction between Cls and the virus (Fig.  1 B). 
HIV-1 Activates the C1 Complex.  The ability of HIV-1 to acti- 
vate C1 was tested by incubating the virions with the reconstituted 
C1 complex for various time periods at 30~  Activation was mea- 
sured through conversion of proenzyme Cls into its active two- 
chain form Cls.  As shown in Fig.  2,  purified HIV-1 was found 
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to activate the C1 complex in a time-dependent fashion. The acti- 
vation rate was comparable to that observed with IgG-OVA im- 
mune complexes. In contrast, no significant C1 activation was in- 
duced by incubation with  the control preparation. 
Recombinant sgp41, but Not Recombinant gpl20,  Binds Clq.  To 
identify the viral component involved in the interaction with the 
Clq subcomponent of C1, recombinant sgl~l and g-p120  were used 
in a solid phase assay. As shown in Fig. 3,  sgp41 bound radiola- 
beled Clq to an extent comparable to that observed with immune 
complexes. In contrast, no significant binding was observed with 
gp120.  Parallel  experiments performed with dimeric proenzyme 
Cls gave no evidence for an interaction between Cls and either 
sgp41  or gp120 (data not shown). 
Recombinant sgp41 Activates the C1 Complex.  With a view to 
test the ability of sgp41 and gp120 to induce C1 activation, the 
reconstituted complex was incubated with increasing amounts of 
these proteins for 20 min at 30~  Under these conditions, sgp41 
was  found  to  induce  activation  of the  C1  complex in  a  dose- 100' 
~9 
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Figure 2.  Kinetics  of C1 activation by HIV-1 and IgG-OVA immune 
complexes. The reconstituted C1 complex (1/tg) was incubated for varying 
periods at 30~  with ([]) Ig-OVA immune complexes (1/zg), (11) HIV-1 
(30 ng of p24), and (A) control preparation. 
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Figure 3.  Clq binding to IgG-OVA  immune complexes  and recombinant 
proteins from HIV-1. Serial dilutions of IgG-OVA immune complexes, 
recombinant proteins, and control protein (BSA) were bound to ELISA 
plates, and subsequent binding of 125I-labded Clq was measured. (11) 
IgG-OVA immune complexes, (O) sgp41, (O) gp120, ([3) BSA. 
dependent manner, less efficiently than IgG-OVA immune com- 
plexes, but more efficiently than heat-aggregated Ig (Fig.  4). In 
contrast to sgp41, gp120 had no significant effect on C1 activation 
within the range tested (Fig.  4). Considering  that recombinant 
proteins obtained from bacterial expression systems are occasion- 
ally contaminated by LPS, a known activator of the C1 complex 
(35), it appeared necessary to verify that the activating effect ob- 
served with sglM1 was not due to trace amounts of LPS. To this 
end, control experiments were performed in the presence of varying 
concentrations of polymixin 13, an antibiotic that binds to LPS and 
thereby abrogates its Cl-activating ability (35). As shown in Table 
1, polymixin B only had a slight inhibitory effect on C1 activation 
by sgp41,  comparable to that observed in the case of IgG-OVA 
immune complexes. This effect likely reflected an inhibition of the 
intrinsic C1 activation mechanism, probably due to C1 dissocia- 
tion, as spontaneous C1 activation (in the absence of activator) was 
significantly slowed down by polymixin B, as illustrated in Table 
1. This hypothesis was further supported by kinetic experiments 
(data not shown). In contrast, activation of C1 by p138, a recom- 
binant protein from EBV, was abolished in the presence of 1 mg/ml 
polymixin B, indicating that this preparation was likely contami- 
nated by LPS. 
Kinetic experiments performed in the presence of polymixin B 
indicated that sgp41  and IgG-OVA immune complexes both in- 
duced a marked increase in the rate of C1 activation, resulting in 
Table  1.  Effect of Polymixin  B  on CI  Activation 
C1  activation 
C1  +  C1  +  C1  +  immune  C1  + 
Polymixin B  buffer  sgp41  complexes  p138 
mg/ml  ~o 
0  5.4  71.8  72.0  68.0 
0.5  4.4  70.6  69.6  19.4 
1.0  3.6  54.4  61.5  3.4 
100 
r 
O 
I  _> 
"~  5o 
4 
I  I  I  I 
activator  (~,g) 
Figure 4.  C1 activation in the presence of varying amounts of IgG- 
OVA immune complexes, aggregated Ig, and recombinant proteins from 
HIV-1. C1 activation was measured after incubation of the reconstituted 
complex (12/~g) for 20 rain at 30~  (O) IgG-OVA complexes; (O) sgp41; 
(11) heat-aggregated Ig; (t)  gp120. 
C1 activation was measured after incubation of the reconstituted com- 
plex for 20 min at 30~  with different activators (sgp41, 42 #g; IgG- 
OVA complexes, 40/~g; p138, 42/~g), in the presence of varying con- 
centrations of polymixin B. 
100 [  . 
~  5o 
0  10  30  50  70  90 
time  (min) 
Figure $.  Kinetics  of C1 activation by lgG-OVA immune complexes 
and recombinant sgp41. The reconstituted C1 complex (12 Izg) was in- 
cubated for varying periods at 30~  in the presence of I mg/ml polymixin 
]3. (11) C1 alone; (O) C1  +  IgG-OVA complexes (28/~g);  (O) C1  + 
sgp41 (28 #g). 
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peptides  (1/~g  per well)  were  dried  onto ELISA  plates. Subsequent  binding 
of 12sI-labeled  Clq (.4) and C3 deposition (B) were measured.  Peptides 
are numbered  according  to reference  29. IC, BSA, control  measurements 
obtained with IgG-OVA immune complexes  (1/~g), and BSA (1 /~g). 
seven- and ninefold  enhancements,  respectively,  after 30 min at 30~ 
(Fig. S). 
Localization of the (?,1 Binding Site(s) in gp41.  To localize 
the C1 binding site(s) within gp41, synthetic peptides span- 
ning the outer membrane part of gp41 (amino acid residues 
531-695  of gp160)  were tested in a Clq binding assay and 
a C3 deposition ELISA. As shown in Fig. 6 A, peptides 60 
and 61 (amino acid residues 591-605  and 601-620)  and, to 
a lesser extent, peptide 57 (amino adds 561-575) had the ability 
to bind 12SI-labeled Clq. Similar results were obtained with 
the C3  deposition ELISA (Fig.  6 B). 
Discussion 
This paper analyzes the molecular basis  of the antibody- 
independent activation of the classical pathway of comple- 
ment by HIV-1 and provides the first experimental evidence 
of: (a) a direct interaction between the virus and the C1 com- 
plex and (b) the ability of the virus to activate the recon- 
stituted  C1  complex.  These  experiments  are  probably 
representing the typical in vivo situation during the first en- 
counter between HIV-1 and the host.  In this first phase of 
Figure 7.  (A) Location of synthetic  peptides from gp41. (B/ack box) 
Putative  HIV immunosuppressive  sequence  (amino  acids  583-599), (shaded 
box) immunodominant  epitope (amino acids 600-609). (B) Amino acid 
sequences of the C1 activating  peptides. Amino acids are numbered  ac- 
cording to reference  63. 
infection,  HIV-1  could  be  targeted  through  antibody-in- 
dependent complement activation to complement receptor- 
positive cells such as monocytes/macrophages (10). The earlier 
suggestion that HIV-1 activates  the classical pathway (8) is 
clearly supported by the direct binding of Clq and activation 
of the C1 complex. These results are further confirmed by 
the experimental data obtained with recombinant proteins 
and synthetic peptides. The fact that the alternative pathway 
was shown to be involved, as stated in a recent report (12), 
remains unclear. We do not want to rule out the possibility 
that the alternative pathway may also be involved in the mech- 
anism described here,  since C3 deposition via the classical 
pathway may lead to subsequent activation of the alternative 
pathway. 
Our results with the human retrovirus are in agreement 
with previous studies indicating direct triggering of the clas- 
sical pathway by animal retroviruses (4). In the case of MuLV 
(the best investigated example), direct attachment of the C1 
complex to the viral surface was also demonstrated (36). How- 
ever, in contrast to HIV-1, both Clq and Cls were shown 
to bind to the viral surface (36). 
To define the viral component responsible for the interac- 
tion  with  the  C1  complex,  we  used  recombinant  sgp41 
(representing the proposed outer membrane part of gp41 [28]) 
and recombinant gp120.  Two different assays (Clq binding 
and C1 activation) gave similar results. Sgp41 was shown to 
interact with Clq and to induce C1 activation, whereas gp120 
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served in the solid phase binding assays may be explained by 
the facts that sgp41 is probably monomeric and that the Clq 
binding affinity is enhanced by multivalent interactions (37). 
On the other hand, the oligomeric state of gp41 on intact 
virions (38, 39) probably favors a multivalent binding of Clq 
and thereby induces rapid activation of the C1 complex. This 
hypothesis is further supported by the observation that ex- 
haustive removal of SDS from the sgp41 preparation both 
induces aggregation of the protein and enhances its activa- 
tion potential (data not shown). The observed binding of 
Clq to sgp41 is reminiscent of previous studies on MuLV, 
where the C1 binding component was identified as p15e, the 
transmembrane protein of MuLV (40). 
The peptide studies demonstrated two potential C1 binding 
sites in gp41.  The major site (amino acids 591-620)  (Fig. 
7 B) includes both the immunodominant (41) and the puta- 
tive immunosuppressive regions (42) of gp41; both regions 
are highly conserved among most retroviruses (43). The second 
site  (amino acids 561-575)  was  less efficient in both Clq 
binding and C3 deposition assays. This site is probably part 
of the region involved in the interaction between gp120 and 
gp41 (44-46).  It should be stressed that none of these se- 
quences contain the ExKxK motif, previously defined as the 
binding site for Clq on the C3,2 domain of IgG (47). 
Interestingly, there is  recent  evidence  that  the epitope 
591-620, which contains the major C1 binding and activating 
sequence, is exposed after sCD4 binding to gp120 (48). This 
change of the steric configuration of the CD4-gp120-gp41 
complex could facilitate the interaction between gp41 and 
the C1 complex. The mechanisms described here probably 
represent the molecular basis for the complement-dependent 
enhancement of HIV-1 infection (9-13), which presupposes 
complement activation independent of antibody. Different 
of this strictly complement-dependent enhancement is the 
proposal of Robinson and Mitchell (49), who showed that, 
in addition to an exclusively antibody-dependent enhance- 
ment (Fc receptor-mediated antibody-dependent enhancement) 
(50-53), a mechanism exists in which complement facilitates 
the antibody-dependent enhancement of infection (comple- 
ment-mediated antibody-dependent enhancement) (11, 13, 
54-59). Besides its enhancing effect on HIV-1 infection, the 
addition of complement also reduced or abrogated the HIV- 
1-neutralizing activity of antibodies (54, 60). Interestingly, 
Robinson  et  al.  (61, 62)  mapped complement-mediated 
antibody-dependent enhancement to a synthetic peptide (amino 
acid residues 586-620), which in our view contains the C1 
activating domain. The common feature between our and 
Robinson's concepts is the role of human complement. Clearly, 
we stress the importance of complement in the preimmune 
phase. 
This report provides experimental evidence of a direct in- 
teraction between the C1 complex and HIV-1, and indicates 
that C1 binding and activation are mediated by specific sites 
in gp41.  We suspect  that this fact is of major importance 
in the early phase of the infection by HIV-1. 
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